Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

The Cancer DegradomeThird-Generation MMP Inhibitors: Recent Advances in the Development of Highly Selective Inhibitors

The Cancer Degradome: Third-Generation MMP Inhibitors: Recent Advances in the Development of... [The association of matrix metalloproteinases (MMPs) with a variety of pathological states has stimulated impressive efforts over the past 20 years to develop synthetic compounds able to block potently and selectively the uncontrolled activity of these enzymes. Extremely potent inhibitors of MMPs have been developed, but in most cases these compounds act as broad-spectrum inhibitors of MMPs. Retrospective analysis suggests that the use of strong zinc-binding groups, like the hydroxamate function, to achieve potent MMP inhibition is responsible not only for the development of inhibitors displaying poor selectivity towards MMP members but also in their ability to potently block other unrelated zinc proteinases. The use of less avid zinc-binding group, like the phosphoryl group present in phosphinic peptide transition-state analogues, has led to a second generation of highly selective MMP inhibitors (MMP-12 selective inhibitors). The third generation of highly selective MMP inhibitors (MMP-13 selective inhibitors) possess no zinc-binding group and exploit the deep S1’ cavity present in some MMPs. Past research on the development of MMP inhibitors has probably underestimated the role of flexibility in the MMP active site and its impact in accommodating different inhibitor structures. Combined use of several biophysical techniques, like nuclear magnetic resonance, X-ray crystallography and isothermal titration experiments, should greatly improve our understanding of the specific structural and dynamic features that can be exploited to obtain series of inhibitors able to specifically block each MMP validated as a therapeutic target.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

The Cancer DegradomeThird-Generation MMP Inhibitors: Recent Advances in the Development of Highly Selective Inhibitors

Editors: Edwards, Dylan; Høyer-Hansen, Gunilla; Blasi, Francesco; Sloane, Bonnie F.
Yiotakis, Athanasios; Dive, Vincent
The Cancer Degradome — Jan 1, 2008
Download PDF
15 pages

Loading next page...
 
/lp/springer-journals/the-cancer-degradome-third-generation-mmp-inhibitors-recent-advances-YyK0KAQdO7

References (43)

Publisher
Springer New York
Copyright
© Springer Science + Business Media, LLC 2008
ISBN
978-0-387-69056-8
Pages
811–825
DOI
10.1007/978-0-387-69057-5_38
Publisher site
See Chapter on Publisher Site

Abstract

[The association of matrix metalloproteinases (MMPs) with a variety of pathological states has stimulated impressive efforts over the past 20 years to develop synthetic compounds able to block potently and selectively the uncontrolled activity of these enzymes. Extremely potent inhibitors of MMPs have been developed, but in most cases these compounds act as broad-spectrum inhibitors of MMPs. Retrospective analysis suggests that the use of strong zinc-binding groups, like the hydroxamate function, to achieve potent MMP inhibition is responsible not only for the development of inhibitors displaying poor selectivity towards MMP members but also in their ability to potently block other unrelated zinc proteinases. The use of less avid zinc-binding group, like the phosphoryl group present in phosphinic peptide transition-state analogues, has led to a second generation of highly selective MMP inhibitors (MMP-12 selective inhibitors). The third generation of highly selective MMP inhibitors (MMP-13 selective inhibitors) possess no zinc-binding group and exploit the deep S1’ cavity present in some MMPs. Past research on the development of MMP inhibitors has probably underestimated the role of flexibility in the MMP active site and its impact in accommodating different inhibitor structures. Combined use of several biophysical techniques, like nuclear magnetic resonance, X-ray crystallography and isothermal titration experiments, should greatly improve our understanding of the specific structural and dynamic features that can be exploited to obtain series of inhibitors able to specifically block each MMP validated as a therapeutic target.]

Published: Jan 1, 2008

Keywords: Catalytic Domain; Nuclear Magnetic Resonance Spectroscopy; Isothermal Titration Calorimetry; Matrix Metalloproteinase Inhibitor; Side Pocket

There are no references for this article.